NuGen Medical Devices (TSX-V:NGMD) Executive Chairman Tony Di Benedetto joined Steve Darling from Proactive to provide details about the company that is developing the next generation of needle-free technologies for both human and animals. Di Benedetto shares with Proactive more about the technology behind products InsuJet and PetJet and also about an assessment and feasibility study in the Netherlands of InsuJet for Semaglutide or its more widely known name Ozempic.
NuGen Medical Devices begins feasibility study in the Netherlands for InsuJet and Ozempic
